PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology

- Primary and Secondary Efficacy Endpoints Met, Demonstrating Statistically - Significant Reduction in Intra-Ocular Pressure (IOP) for Patients with Glaucoma MELBOURNE, Australia, Feb. 18, 2022 /PRNewswire/ -- PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular implants with sustained drug delivery for patients suffering from ophthalmic diseases such as glaucoma, today announced that the...

Related Keywords

Australia ,Melbourne ,Victoria ,Canada ,Toronto ,Ontario ,San Francisco ,California ,United States ,Australian ,Like Ahmed ,Russell Tait ,Michael Coote ,Polyactiva Pty Ltd ,Prezia Technology ,Drug Delivery Technology ,University Of Utah ,Horizons Forum ,University Of Toronto ,Prezia Sustained Drug Delivery Technology ,Prism Eye Institute In Ontario ,Secondary Efficacy Endpoints Met ,Intra Ocular Pressure ,Ocular Implant ,Primary Open Angle Glaucoma ,Chief Executive Officer ,Annual Glaucoma ,Associate Professor Michael Coote ,Melbourne Eye Specialists ,Prism Eye Institute ,Assistant Professor ,Clinical Professor ,Sustained Drug Delivery Technology ,